Helicobacter pylori (Hp) contributes to the development of gastric and extra-gastric diseases such as autoimmune thyroiditis (AT), and causes persistent life-long infection despite local and systemic immune response. We determined the specific cellular immune response to Hp antigens and PWM (control mitogen) in two groups of Hp infected patients--group A (n = 21), involving patients with autoimmune thyroiditis and group B (n = 13) of patients without AT--using modified lymphocyte transformation test before and after eradication therapy in comparison with healthy controls (group C, n = 15). Immune reactivity to the majority of Hp antigens (aHp, hHp, HpAg, CagA) was significantly lower in group B before eradication therapy in comparison with healthy Hp negative controls. A significant increase in immune reactivity was observed in group B to certain Hp antigens after successful eradication. The same levels (but insignificant) of immune reactivity were shown in group A. Our results indicate that Hp can cause the inhibition of the specific cellular immune response in Hp infected patients with or without autoimmune diseases such as AT, which can be abrogated by successful eradication of Hp. Lymphocyte transformation test appears to be a good tool for detection of immune memory cellular response in patients with Hp infection.

Institute of Immunology and Microbiology 1st Faculty of Medicine Charles University Prague Prague Czech Republic

Zobrazit více v PubMed

Clin Sci (Lond). 2006 Mar;110(3):305-14 PubMed

Neuro Endocrinol Lett. 2004 Jun;25(3):211-8 PubMed

Med Microbiol Immunol. 2010 May;199(2):109-16 PubMed

J Clin Immunol. 1996 Jan;16(1):31-40 PubMed

J Exp Med. 1998 Jan 5;187(1):135-40 PubMed

J Clin Gastroenterol. 2007 Jul;41(6):548-58 PubMed

J Infect Dis. 2004 May 15;189(10):1914-20 PubMed

Med Microbiol Immunol. 1993 May;182(2):63-76 PubMed

Gut. 2005 Jan;54(1):25-32 PubMed

J Physiol Pharmacol. 1996 Mar;47(1):195-202 PubMed

Helicobacter. 2006 Oct;11 Suppl 1:46-51 PubMed

J Clin Gastroenterol. 1998 Jun;26(4):259-63 PubMed

Rev Physiol Biochem Pharmacol. 2004;152:205-20 PubMed

Clin Exp Immunol. 1991 Mar;83(3):396-400 PubMed

Gut. 1997 Mar;40(3):297-301 PubMed

Neuro Endocrinol Lett. 2003 Feb-Apr;24(1-2):57-64 PubMed

Microsc Res Tech. 2001 Jun 15;53(6):419-24 PubMed

Proc Natl Acad Sci U S A. 2004 May 18;101(20):7727-32 PubMed

Helicobacter. 2008 Feb;13(1):1-19 PubMed

Southeast Asian J Trop Med Public Health. 2001 Mar;32(1):88-94 PubMed

Diagn Microbiol Infect Dis. 2007 Jan;57(1):27-34 PubMed

Acta Gastroenterol Belg. 2000 Oct-Dec;63(4):388-92 PubMed

J Gastroenterol. 2009;44(4):239-48 PubMed

Immunol Lett. 2004 May 15;93(2-3):97-108 PubMed

Infect Immun. 2005 Jan;73(1):523-31 PubMed

J Exp Med. 2003 Dec 15;198(12):1887-97 PubMed

Neuro Endocrinol Lett. 2006 Dec;27 Suppl 1:25-30 PubMed

Best Pract Res Clin Gastroenterol. 2007;21(2):237-59 PubMed

Presse Med. 1967 Feb 25;75(10):461-5 PubMed

Endocr Rev. 1993 Feb;14(1):107-20 PubMed

Clin Endocrinol (Oxf). 2004 Nov;61(5):650-2 PubMed

J Infect. 2007 Mar;54(3):257-61 PubMed

Gut. 1994 Oct;35(10):1379-84 PubMed

J Immunol. 2006 Mar 1;176(5):3000-9 PubMed

Helicobacter. 2006 Feb;11(1):21-30 PubMed

Helicobacter. 2008 Aug;13(4):295-303 PubMed

Zentralbl Bakteriol. 1993 Sep;280(1-2):166-76 PubMed

Folia Microbiol (Praha). 2007;52(1):91-4 PubMed

Dig Liver Dis. 2008 Aug;40(8):619-26 PubMed

J Clin Invest. 2004 Feb;113(3):321-33 PubMed

J Physiol Pharmacol. 1999 Dec;50(5):817-26 PubMed

Detection of primary clarithromycin resistance of Helicobacter pylori and association between cagA (+) status and clinical outcome